Efficacy and safety of bimatoprost 0.01% formulated in tight junction modulation technology compared to marketed benzalkonium chloride preserved bimatoprost 0.01% ophthalmic solution in healthy beagle dogs


  • Arindam Halder Department of Formulation Development, Sun Pharmaceutical Industries Limited, Vadodara, Gujarat, India
  • Vinod Burade Department of Biological Research Pharmacology, Sun Pharma Laboratories Ltd, Mumbai, Maharashtra, India
  • Ajay J. Khopade Department of Formulation Development, Sun Pharmaceutical Industries Limited, Vadodara, Gujarat, India
  • Amit Thavkar Department of Medical Services, Sun Pharma Laboratories Ltd, Mumbai, Maharashtra, India




Tight Junction modulation technology, Bimatoprost 0.01%, Intraocular pressure, Polyhexamethylene biguanide hydrochloride, Glaucoma


Background: This study was undertaken to compare the efficacy and safety of the new technology tight junction modulation (TJM) bimatoprost 0.01% (TJM-bimatoprost), containing polyhexamethylene biguanide hydrochloride as a preservative, and marketed bimatoprost 0.01% (BKC-bimatoprost) in healthy beagle dogs.

Methods: This was a cross-over study and all animals in the study were assigned to one of two treatment arms to receive either TJM-bimatoprost (n=6) or BKC-bimatoprost (n=6) ophthalmic solution. Dosing for period 1 was started on day 3 (8 am everyday) and it continued till day 12. Assessments were carried out every day at 8 am, 9 am, 2 pm and 8 pm throughout the study period till day 17.

Results: For the pooled analysis (n=12 in each group) of period 1 and 2, there was a significant decrease (p<0.001) in mean intra-ocular (IOP) 1 hour post administration as compared to the baseline and this trend continued all throughout the study in both treatment arms. Twenty fours after last dose, on day 12, IOP measurements were 14.20±1.59 mmHg and 13.89±1.5 mmHg in the TJM-bimatoprost and the BKC-bimatoprost group respectively. The analysis of the primary end point revealed that 95% confidence interval for the between group differences in mean IOP values were well within the pre-defined equivalence margin of ±1.5 mmHg. In terms of safety, there was no difference in mean pupillary diameter in the TJM-bimatoprost and BKC-bimatoprost group.

Conclusions: The results of this study enhance our understanding of the proprietary TJM technology by establishing efficacy and safety of TJM-bimatoprost in animal models. 

Author Biography

Ajay J. Khopade, Department of Formulation Development, Sun Pharmaceutical Industries Limited, Vadodara, Gujarat, India

Dr Ajay J Khopade

Vice President, Formulation Development

Ajay.Khopade@Sunpharma.com, 9924363638


Sambhara D, Aref AA. Glaucoma management: relative value and place in therapy of available drug treatments. Ther Adv Chronic Dis. 2014;5(1):30-43.

European Glaucoma Society. Terminology and guidelines for glaucoma. 3rd ed. Savona: Editrice DOGMA; 2008.

Weinreb RN, Toris CB, Gabelt BAT, Lindsey JD, Kaufman PL. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol. 2002;47(1):53-64.

Valk VDR, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112(7):1177-85.

Novack GD, Donnell OMJ, Molloy DW. New glaucoma medications in the geriatric population: efficacy and safety. J Am Geriatr Soc. 2002;50(5):956-62.

Wirta D, Vandenburgh AM, Weng E, Whitcup SM, Kurstjens S, Beddingfield FC. Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials. Clin Ophthalmol. 2011;5:759-65.

McCarey B, Edelhauser H. In vivo corneal epithelial permeability following treatment with prostaglandin analogs (correction of analoges) with or without benzalkonium chloride. J Ocul Pharmacol Ther. 2007;23(5):445-51.

Myers JS, Vold S, Zaman F, Williams JM, Hollander DA. Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12 weeks trials. Clin Ophthalmol. 2014;8:643-52.

Chen YY, Wang TH, Liu C, Wu KY, Chiu SL, Simonyi S, et al. Tolerability and efficacy of bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01% (APPEAL Taiwan) study. BMC Ophthalmol. 2016;16(1):162.

Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Baudouin BF. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005;46(7):2444-50.

Steven DW, Alaghband P, Lim KS. Preservatives in glaucoma medication. Br J Ophthalmol. 2018;102(11):1497-503.

Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17(3):341-9.

Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86(4):418-23.

Farshori P, Kachar B. Redistribution and phosphorylation of occlude in during opening and resealing of tight junctions in cultured epithelial cells. J Membr Biol. 1999;170(2):147-56.

Findley MK, Koval M. Regulation and roles for claudin-family tight junction proteins. IUBMB Life. 2009;61(4):431-7.

Ikeda T, Ledwith A, Bamford CH, Hann RA. Interaction of a polymeric biguanide biocide with phospholipid membranes. Biochim Biophys Acta. 1984;769(1):57-66.

Chadeau E, Dumas E, Adt I, Degraeve P, Noel C, Girodet C, et al. Assessment of the mode of action of polyhexamethylene biguanide against Listeria innocua by Fourier transformed infrared spectroscopy and fluorescence anisotropy analysis. Can J Microbiol. 2012;58(12):1353-61.

Mashat BH. Polyhexamethylene biguanide hydrochloride: features and applications. British Journal of Environmental Sciences. 2016;4(1):49-55.

Castillo Y, Ernest J. Inventor; Alcon Laboratories Inc Inc., assignee. Sustained release and comfortable ophthalmic composition and method for ocular therapy. United States patent US 4,867,749; 2000.

Larkin DF, Kilvington S, Dart JK. Treatment of Acanthamoeba keratitis with polyhexamethylene biguanide. Ophthalmology. 1992;99(2):185-91.

Sutton SV, Porter D. Development of the antimicrobial effectiveness test as USP chapter <51>. PDA J Pharm Sci Technol. 2002;56(6):300-11.

Pereira S, Tettamanti M. Ahimsa and alternatives: The concept of the 4th R, The CPCSEA in India. ALTEX. 2005;22:3-6.

Woodward DF, Liang Y, Krauss AH. Prostamides (prostaglandin-ethanolamides) and their pharmacology. Br J Pharmacol. 2008;153(3):410-9.

Lee SS, Dibas M, Almazan A, Robinson MR. Dose-Response of Intracameral Bimatoprost Sustained-Release Implant and Topical Bimatoprost in Lowering Intraocular Pressure. J Ocul Pharmacol Ther. 2019;35(3):138-44.

Gelatt KN, Mackay EO. Effect of different dose schedules of bimatoprost on intraocular pressure and pupil size in the glaucomatous Beagle. J Ocul Pharmacol Ther. 2002;18(6):525-34.

Kato K, Woerdt VDA. Effect of Long-term Topical Application of 0.005% Latanoprost on Intraocular Pressure Uncontrolled by Multiple or Single Drug Therapy in Dogs with Secondary Glaucoma. 2017;6(1). Available at https://www.scitechnol.com/peer-review/effect-of-longterm-topical-application-of-0005-latanoprost-on-intraocular-pressure-uncontrolled-by-multiple-or-single-drug-therapy-3Mof.php?article_id=5856. Accessed on 19 March 2020.




How to Cite

Halder, A., Burade, V., Khopade, A. J., & Thavkar, A. (2020). Efficacy and safety of bimatoprost 0.01% formulated in tight junction modulation technology compared to marketed benzalkonium chloride preserved bimatoprost 0.01% ophthalmic solution in healthy beagle dogs. International Journal of Basic & Clinical Pharmacology, 9(8), 1210–1216. https://doi.org/10.18203/2319-2003.ijbcp20203087



Original Research Articles